Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer/GSK Levitra EU approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bayer/GlaxoSmithKline's erectile dysfunction therapy Levitra (vardenafil) receives marketing authorization in Europe, firms announce March 7. Approval of the PDE-5 inhibitor is based on clinical studies in 3,750 men. The Summary of Product Characteristics states that Levitra allows some men to attain an erection as early as 15 min. after dosing (25 min. for most men) and for up to nearly five hours after dosing, the firms say. The recommended starting dose of Levitra is 10 mg 25 to 60 min. before sexual activity. Vardenafil received a positive opinion from the European Committee for Proprietary Medicinal Products Nov. 21, 2002 (Pharmaceutical Approvals Monthly, Dec. 1, 2002, In Brief). Lilly ICOS' Cialis (tadalafil) beat Levitra to market with its Nov. 12, 2002 EU approval (see related story, p. 3). Tadalafil and vardenafil are both currently "approvable" at FDA, pending submission of additional short-term clinical pharmacology studies for each ED agen

You may also be interested in...

Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.

‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars

Marking a decade since Celltrion’s Remsima version of infliximab became the first monoclonal antibody biosimilar approved in Europe, Kevin Byoung Seo Choi, senior vice president and head of the marketing division at Celltrion Healthcare, talks to Generics Bulletin about the firm’s progress so far and the “room for improvement” that the company perceives in areas such as regulation, market access and pricing, supply chain and procurement – as well as what the future holds for the Korean biosimilars giant.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts